FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma
Evidence for efficacy in the adjuvant treatment of patients with high-risk urothelial carcinoma is based on the results of CHECKMATE-274 study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Evidence for efficacy in the adjuvant treatment of patients with high-risk urothelial carcinoma is based on the results of CHECKMATE-274 study
The results from a phase I study with tumour-infiltrating lymphocytes infusion in patients with metastatic non-small cell lung cancer
It also approved the VENTANA MMR RxDx Panel as a companion diagnostic device to select patients
Findings from a phase III study of hippocampal avoidance during prophylactic cranial irradiation in patients with small-cell lung cancer
Study findings point to potential to integrate prior antibiotic exposure in decision-making process for first-line treatment of advanced non-small cell lung cancer
Hypoxia-inducible factor inhibitor was investigated in the ongoing Study 004
The 51-gene expression-based liquid biopsy accurately diagnoses neuroendocrine tumours and is an effective surrogate marker compared to chromogranin A
Evidence for efficacy of combination treatment is based the results of the CLEAR study
Findings from a systematic review and safety meta-analysis of placebo-controlled randomised controlled studies with a median follow-up ranging up to 78 months
Findings from the SOLE and SOLE Estrogen Substudy in postmenopausal women with hormone receptor-positive, lymph node-positive, operable breast cancer
Findings from a retrospective cohort study determine no association between dose of dexamethasone and rate of hypersensitivity reactions
Findings from an analysis of the clinical efficacy of COVID-19 vaccination in a large series of patients with cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.